Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-based therapy in paediatric high-grade glioma
2010-022189-28Phase 2Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioma and anaplastic ependymoma (2 arms), sponsored by Roche. Primary endpoint: Event-free survival. Started May 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
gliomaanaplastic ependymoma
Beyond the preview
Go deeper on 2010-022189-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022189-28.